DataMEDS AI, Inc. (NASDAQ: MEDS) said it has completed its acquisition of Helomics Corporation from Axe Compute Inc. (NASDAQ: AGPU) for $1.5 million, marking DataMEDS' entry into the oncology diagnostics space.
The target, a Pittsburgh-based functional precision medicine platform that applies artificial intelligence to tumor data, was a wholly-owned subsidiary of Axe Compute. It represents the final operating unit remaining from Axe Compute's predecessor identity as Predictive Oncology Inc., prior to that company's name change in December 2025.
The transaction was structured as common shares and an acquisition note, and includes the business's CLIA/CAP-certified clinical laboratory and equipment, as well as the Predictive Oncology contract research organization central lab services. DataMEDS also received $1.5 million in cash as part of the deal. The acquisition carries no third-party debt requiring repayment and no outstanding unpaid accounts payable beyond ongoing monthly operational expenses.
Gerald Commissiong, interim co-CEO of DataMEDS, said the company aims to leverage the acquisition to address gaps in patient outcomes, particularly in rural areas. "We are thrilled to have completed this strategic transaction that thrusts DataMEDS into the field of oncology, where we know there is a tremendous need to improve patient outcomes, especially in rural areas," Commissiong said.
Chris Miglino, chief executive officer of Axe Compute, said the structure of the exit allowed Axe Compute to retain a shareholder stake in Helomics' future. "We were pleased to structure our exit from the cancer testing business in a way that allows us to maintain a position as shareholders in the future of AI Helomics," Miglino said.
DataMEDS is a Health IT company that integrates technology, pharmacy, and telemedicine business units. Helomics will join those operations as the company's oncology diagnostic platform.
Additional details on the transaction are expected to be disclosed in a Form 8-K filing with the Securities and Exchange Commission, according to the companies.
The announcement was published September 15, 2026.
